Morpheus8 Burst / Deep Burst & Exosomes

Tiny microneedles create controlled micro-channels while delivering RF energy beneath the skin. This controlled energy stimulates a wound-healing response and supports collagen and elastin remodeling, helping improve skin firmness and texture over time.

Burst can be a useful option for patients seeking treatment across multiple tissue depths. The most appropriate approach depends on your skin, treatment area and desired outcome. Your clinician will select the settings and treatment approach following assessment.

Most patients tolerate treatment well with appropriate topical numbing. Areas such as the jawline, neck and around the mouth can feel more intense. Comfort measures can be tailored according to your sensitivity.

A typical treatment plan may involve 1–3 sessions spaced around 4–6 weeks apart. Some patients may benefit from maintenance treatment every 6–12 months depending on skin quality and their individual goals.

Early improvements in glow and texture may become noticeable within 1–3 weeks. Skin tightening and collagen remodeling generally build over 6–12 weeks and can continue developing for several months.

Redness, mild swelling and a sandpaper-like skin texture can occur for several days. Some patients may experience tiny grid marks or pinpoint scabs. Many people return to normal activities within 24–72 hours, depending on treatment intensity.

Possible effects include redness, swelling, bruising, temporary dryness and post-inflammatory hyperpigmentation. The risk of pigmentation changes can be higher in deeper skin tones if aftercare is not followed. Rare complications can include infection or prolonged sensitivity. A proper assessment and aftercare plan are important.

Morpheus8 may not be suitable during pregnancy or breastfeeding, with an active skin infection, certain uncontrolled medical conditions affecting healing, certain implanted electrical devices, or a history of poor wound healing or keloids. Suitability is assessed individually.

It may be combined with other treatments such as skin boosters, peels, IPL or laser depending on timing, skin condition and treatment goals. Regenerative add-ons such as exosome-style products may also be considered following clinical assessment.

Exosomes are tiny cell-to-cell messenger particles containing signaling molecules such as proteins and RNA. In aesthetics, exosome-style extracellular vesicle products may be used as a supportive add-on following procedures such as RF microneedling or laser treatment.

No. Exosome products are not live cells. They are generally extracellular vesicle preparations derived from cultured cells and processed according to the specific product and its regulatory framework.

In some aesthetic protocols, exosome-style products are applied topically following microneedling or RF microneedling to take advantage of temporary micro-channels. Application depends on the specific product instructions and applicable clinical and regulatory requirements.

Exosome-style products are generally used as a supportive regenerative add-on rather than a replacement for the primary procedure. Patients may notice improvements in the appearance of glow, texture and recovery, but results vary according to baseline skin health and the procedure they are combined with.

Morpheus8 Burst creates controlled micro-injury and stimulates collagen remodeling. Exosome-style products may be used as a supportive add-on during the recovery phase, with the aim of supporting the skin environment and overall skin quality.

Many patients achieve their desired outcome through a planned course of treatment rather than a single session. Maintenance treatment may also be considered depending on skin laxity, skin quality and individual goals.

Morpheus8 can be suitable for many darker skin tones when appropriate settings and aftercare are used. Conservative energy selection, careful treatment protocols and strict sun protection are important because post-inflammatory hyperpigmentation can occur.

Where an appropriate product is selected, bovine-derived extracellular vesicle or exosome-style preparations may be preferred for their mammalian origin, manufacturing consistency and available quality documentation. Product selection depends on sourcing, processing, testing, clinical protocol and applicable regulations.

Not exactly. Many products marketed as plant exosomes are more accurately described as plant-derived extracellular vesicles. Their biological composition differs from mammalian extracellular vesicles, so they should not be treated as identical products.

Mammalian extracellular vesicles can contain signaling components associated with mammalian cell-to-cell communication. This is one factor clinicians may consider when selecting an extracellular vesicle product for use alongside collagen-inducing aesthetic procedures.

Bovine-derived extracellular vesicle products can offer consistent sourcing and scalable manufacturing when produced by reputable suppliers. Appropriate documentation, traceability, batch testing, sterility or endotoxin controls and storage requirements are important considerations when selecting any clinical product.

Product selection can involve both biological considerations and quality controls. Relevant factors include the product’s composition, manufacturing controls, traceability, testing, storage requirements and suitability for the intended clinical protocol.

No. Plant-derived extracellular vesicles may have applications in areas such as hydration, soothing and barrier support. Different products have different compositions and evidence bases, so the appropriate option depends on the intended use and clinical protocol.

Patients with concerns about bovine-derived materials, including ethical, dietary or sensitivity concerns, should discuss these before treatment. The clinical team can review the available options and determine an appropriate approach based on individual circumstances.

Product selection should consider supplier documentation, traceability, batch testing, sterility and endotoxin information where applicable, storage requirements and appropriate handling. The product must also be used according to its intended application and the clinic’s clinical protocol.